What Are the Risk Factors for Bladder Cancer?

Smoking is the single largest risk factor for bladder cancer, but the full list extends well beyond tobacco. Occupational chemical exposure, arsenic and disinfection byproducts in drinking water, inherited genetic variants, chronic bladder inflammation, certain medications, and even some herbal products all contribute to a person’s overall risk. The disease strikes men roughly four times more often than women, and some of the reasons behind that gap are still being worked out. Understanding these risk factors matters because many of them are modifiable, and because bladder cancer is among the more common cancers worldwide yet receives relatively little public attention.

Smoking and Its Outsized Role

Tobacco smoking accounts for the largest share of bladder cancer cases. A large meta-analysis of 89 observational studies found that current smokers had about three times the risk of bladder cancer compared with people who never smoked, and former smokers still carried roughly double the risk.¹ A large U.S. cohort study put the numbers even higher, with current smokers showing about a fourfold increase in risk.² The mechanism is straightforward in concept: many of the carcinogens in cigarette smoke are filtered by the kidneys and collect in the bladder, where they sit in contact with the bladder lining for hours at a time.

Quitting helps, but the residual risk lingers for years. In that same meta-analysis, the benefit of cessation was most apparent about 20 years out from the quit date. A pooled analysis of ten Japanese cohort studies found that men who had quit for more than a decade no longer had a statistically significant increase in risk compared with never smokers, though the point estimate still trended above baseline.³ The U.S. data showed that even people who quit more than ten years before enrollment still had elevated risk relative to never smokers.² So quitting clearly reduces risk in a dose-dependent way, but it does not reset the clock to zero.

Risk also climbs with cumulative exposure. The Japanese pooled analysis showed a linear increase in risk with increasing pack-years in men.³ The meta-analysis of 89 studies found a plateau effect for smoking intensity, meaning that going from, say, half a pack a day to a full pack raises risk substantially, but the risk increase flattens out at very high consumption levels. This is unusual among smoking-related cancers and may reflect saturation of the bladder lining’s exposure to carcinogens.¹

Workplace Chemical Exposures

After smoking, occupational exposure is the next most well-established risk factor. The culprits are primarily aromatic amines, a class of industrial chemicals. The most important ones include 2-naphthylamine, 4-aminobiphenyl, and benzidine. These chemicals turn up in the products of the dye, rubber, chemical manufacturing, paint, and plastics industries, and also in motor vehicle exhaust.⁴ Workers exposed to dyes in the textile industry face elevated risk, particularly in regions where regulation of these chemicals has been limited.⁵

Firefighters represent a more recently recognized occupational risk group. A meta-analysis found a statistically significant association between firefighting and bladder cancer.⁶ Their exposure profile is complex: combustion products, diesel exhaust from fire apparatus, and per- and polyfluoroalkyl substances (PFAS) in firefighting foam all play potential roles. A study of Norwegian firefighters found that those with moderate diesel exhaust exposure had roughly double the risk of urinary tract cancer.⁷ The fact that risk was elevated in the middle tertile of exposure but not the highest is a quirk that may reflect exposure measurement challenges rather than a real biological pattern.

Arsenic and Disinfection Byproducts in Drinking Water

Long-term exposure to arsenic in drinking water is a firmly established bladder carcinogen. A systematic review spanning 30 years of evidence found that even at relatively low arsenic levels, bladder cancer incidence rose, and the dose-response relationship was consistent: predicted risk roughly doubled at 50 micrograms per liter and climbed further at higher concentrations.⁸ A U.S.-based study found that people with the highest cumulative arsenic exposure from drinking water over 40 years had more than double the odds of developing bladder cancer compared to those with the lowest exposure.⁹ Once ingested, arsenic is processed by the liver into forms the body can excrete, but the bladder ends up bathed in those metabolites during the excretion process.

A separate concern is trihalomethanes, the chemical byproducts created when chlorine or other disinfectants react with organic matter in water. A dose-response meta-analysis found that bladder cancer risk became significantly elevated at trihalomethane concentrations above about 41 micrograms per liter, with the highest-exposed groups showing roughly a third more risk than the lowest-exposed groups.¹⁰ One case-control study found even higher risk among people who consumed the most tap water at points in the distribution system where the water was oldest after disinfection.¹¹ This is a tricky public health problem because chlorination prevents waterborne infectious disease; the solution is not to stop disinfecting water but to reduce the organic precursors or switch to disinfection methods that produce fewer byproducts.

Genetic Susceptibility

Your genes do not cause bladder cancer on their own in most cases, but they can raise or lower your vulnerability to the carcinogens described above. Two gene variants have been studied in particular detail. People with the NAT2 slow-acetylator genotype, which affects how quickly the body detoxifies aromatic amines, have about a 40 percent higher risk of bladder cancer overall. That risk is especially pronounced among smokers, because cigarette smoke delivers the same aromatic amines that NAT2 helps neutralize.¹² The GSTM1 null genotype, a deletion of a gene involved in clearing reactive chemicals, roughly doubles bladder cancer risk in people missing both copies, independent of smoking status.¹²

Beyond those two well-known variants, genome-wide association studies have identified at least 24 independent markers reaching strong statistical significance for bladder cancer susceptibility. A polygenic risk score based on those markers showed roughly a fourfold difference in lifetime bladder cancer risk between people in the lowest and highest risk deciles, and that gap held for both smokers and nonsmokers.¹³ An earlier study found that seven specific variants, including GSTM1 null, could collectively help estimate inherited bladder cancer risk, with individual odds ratios ranging from about 1.13 to 1.65.¹⁴ None of these individual variants are destiny on their own, but in combination, and especially layered on top of environmental exposures, they meaningfully shift the risk landscape.

Why Men Get Bladder Cancer Far More Often Than Women

Bladder cancer incidence is roughly four times higher in men than in women in the United States, and a similar disparity exists globally.¹⁵ Historically, people assumed this was entirely explained by higher smoking rates and greater occupational chemical exposure among men. Those exposures do explain part of the gap, but animal studies have shown that male animals also develop bladder cancer at higher rates than females after treatment with aromatic amines, even when exposure levels are identical. This suggests a biological component as well.

The leading hypothesis involves sex hormones and the liver. Androgens appear to promote bladder carcinogenesis while estrogens may have a protective effect, and the liver’s metabolic enzymes, which decide how much active carcinogen ultimately reaches the bladder via urine, are themselves influenced by sex hormone levels.¹⁵ The paradox is that while women develop bladder cancer less often, they tend to have worse outcomes. Women are more likely to be diagnosed with advanced disease and with non-urothelial subtypes, and they tend to have higher recurrence rates and poorer prognosis overall.¹⁶ This may partly reflect delayed diagnosis, since blood in the urine in women is sometimes initially attributed to other causes like urinary tract infections or menstruation, but differences in tumor biology appear to play a role as well.¹⁷

Chronic Bladder Inflammation and Catheter Use

Anything that keeps the bladder chronically irritated and inflamed increases cancer risk over time. The most dramatic example is schistosomiasis, a parasitic infection widespread in parts of the Middle East and Africa. Bladder cancer is actually the most common malignancy in those regions, and the geographic correlation between schistosomiasis and bladder cancer is strong and consistent across epidemiological, clinical, and animal data.¹⁸ Schistosomiasis-associated bladder cancer tends to be squamous cell carcinoma rather than the transitional cell carcinoma more common in Western countries, and it tends to occur at younger ages.

In high-income countries, chronic indwelling urinary catheters represent a comparable source of prolonged bladder irritation. A population-based study from Ontario, Canada, found that chronic catheterization was associated with roughly a fivefold increase in bladder cancer risk, and each additional urinary tract infection added a small but statistically significant increment of risk on top of that.¹⁹ Another large analysis found a similar magnitude of risk for patients with chronic indwelling catheters, and also identified benign prostatic hyperplasia and urinary tract stones as independent contributors to increased bladder cancer risk.²⁰ People with spinal cord injuries or neurogenic bladder who require long-term catheterization are therefore a recognized high-risk group who often receive ongoing surveillance.

Prior Cancer Treatments

Certain cancer treatments can themselves cause bladder cancer years later. Cyclophosphamide, an alkylating chemotherapy drug still used for lymphomas and autoimmune diseases, is an established bladder carcinogen. A study of patients treated for non-Hodgkin’s lymphoma found an overall 4.5-fold increase in bladder cancer risk after cyclophosphamide therapy, and the risk climbed steeply with cumulative dose, reaching roughly 14.5-fold in patients who received the highest cumulative doses.²¹ Cyclophosphamide produces a toxic metabolite called acrolein that collects in the bladder, which is why the protective drug mesna is often co-administered today to neutralize it.

Pelvic radiation therapy is another treatment that raises bladder cancer risk. A study examining patients treated for endometrial cancer found that both external-beam radiation and brachytherapy were independently associated with a higher incidence of secondary bladder cancer compared to the general population.²² The bladder sits in the radiation field when the pelvis is being treated, and the cumulative DNA damage over time can trigger malignant transformation. This risk is relevant for survivors of cervical, endometrial, rectal, and prostate cancers who received pelvic radiation, though the absolute risk remains relatively small for any individual patient.

Pioglitazone and Diabetes Treatment

The diabetes drug pioglitazone, a thiazolidinedione used to improve insulin sensitivity, has been under scrutiny for a possible link to bladder cancer since the early 2010s. A systematic review and meta-analysis found that short-term use (under a year) was not associated with increased risk, but use beyond two years was linked to about a 50 percent higher risk of bladder cancer, and there was a significant dose-response relationship.²³ A large population-based cohort study reported similar findings, with use beyond two years carrying roughly 78 percent higher risk.²⁴ An earlier interim cohort analysis found no overall risk increase but did detect elevated risk in the subgroup that used pioglitazone for more than 24 months.²⁵

The related drug rosiglitazone, another thiazolidinedione, has not shown the same association with bladder cancer risk.²⁴ This suggests the risk is specific to pioglitazone rather than to the drug class as a whole. The absolute increase in risk is modest for any one patient, but for someone with diabetes who has other bladder cancer risk factors, such as smoking history, the cumulative picture matters. Several regulatory agencies have added warnings to pioglitazone’s labeling, and the drug has been pulled from the market in some countries entirely.

E-Cigarettes and Unknown Long-Term Effects

The relationship between e-cigarettes and bladder cancer is one of the emerging concerns in urology. While no one has yet documented an increase in bladder cancer rates among e-cigarette users (the products have not been around long enough for that), the chemical signals are worrying. A systematic review found that e-cigarette users have higher urinary concentrations of several carcinogens with established links to bladder cancer compared to non-users.²⁶ A study comparing 13 e-cigarette users with 10 non-users found significantly higher levels of two specific bladder carcinogens, o-toluidine and 2-naphthylamine, in the urine of vapers.²⁷ 2-naphthylamine is the same aromatic amine that drove the bladder cancer epidemic among dye workers in the early 20th century.

The levels found in e-cigarette users are lower than those in combustible cigarette smokers, but the fact that recognized bladder carcinogens appear in the urine at all undermines any assumption that vaping is entirely safe from a bladder standpoint. Given that bladder cancer has a typical latency of decades from first exposure, it will likely be the 2030s or 2040s before epidemiological data can confirm or rule out a meaningful increase in risk among long-term vapers.

Aristolochic Acid in Herbal Products

Aristolochic acid, a naturally occurring compound found in certain plants of the Aristolochia family, is a potent carcinogen to the urinary tract. In traditional Chinese medicine, herbs containing aristolochic acid, such as Mu Tong, have been prescribed for conditions including urinary tract infections and edema. A population-based case-control study in Taiwan found a significant dose-response relationship: people prescribed more than 60 grams of Mu Tong or who consumed an estimated total of more than 150 milligrams of aristolochic acid had meaningfully elevated risk of urinary tract cancer.²⁸ A study of patients with end-stage renal disease found even stronger associations, with each additional 30 grams of Mu Tong prescribed linked to a 30 percent increase in urinary tract cancer risk.²⁹

Aristolochic acid is now banned or restricted in many countries, but products containing it still circulate in some traditional medicine markets. The risk is worth knowing about because it can be completely avoided, and because the herbal products involved are sometimes marketed as natural remedies without clear labeling of their aristolochic acid content.

Personal Hair Dye Use

Given that occupational exposure to dye chemicals is a well-known bladder cancer risk factor, it is natural to wonder whether using hair dye at home carries a similar risk. The evidence here is largely reassuring. A Dutch case-control study found no association between personal use of either temporary or permanent hair dyes and bladder cancer risk, regardless of duration, frequency, or color of dye used.³⁰ A U.S. population-based case-control study similarly found no overall association in men or women.³¹

There was one notable exception in the U.S. study: women who exclusively used permanent hair dyes and carried the NAT2 slow-acetylator genotype, the same metabolic variant discussed above, showed a substantially elevated risk. This suggests that personal hair dye use may interact with specific genetic backgrounds to increase risk in a small subset of users. For the general population, though, home hair dye use does not appear to be a meaningful bladder cancer risk factor. The concentrations and duration of chemical contact involved in personal use are vastly different from the chronic industrial exposures that drove the original occupational findings.

Racial and Ethnic Differences in Incidence and Outcomes

Bladder cancer incidence varies sharply by race and ethnicity in the United States. Non-Hispanic white people have the highest incidence rate overall, followed by Black people, then Hispanic white people, with Asian and Pacific Islanders having the lowest rates.³² But incidence does not tell the whole story. Black patients consistently present at more advanced stages and have the worst survival outcomes of any racial group. Five-year disease-specific survival was roughly 83 percent in white patients compared with about 70 percent in Black patients, and that gap persisted even after adjusting for stage and grade.³³

The reasons for this disparity are likely layered. Differences in access to care and time to diagnosis contribute to later-stage presentation. But even within the same stage, survival differences persist, suggesting that biological differences in tumor behavior, differences in treatment offered, and systemic inequities in healthcare delivery all play a role. One epidemiological observation adds another wrinkle: for squamous cell carcinoma of the bladder specifically, Black patients actually have a higher incidence rate than non-Hispanic white patients, even though non-Hispanic white patients lead in overall bladder cancer incidence.³² Squamous cell carcinoma is the subtype most strongly associated with chronic inflammation and infection, which may point to differing exposure patterns across populations.

Diet, Fluid Intake, and the Limits of the Evidence

Dietary factors are where the evidence for bladder cancer risk becomes considerably less clear-cut than for smoking or chemical exposure. A review of evidence-based dietary principles identified certain foods associated with increased risk, including pork, barbecued meats, high-fat diets, and excessive coffee consumption.³⁴ However, no clear association has been established for beef, eggs, processed meats in general, or total fluid intake.³⁵

The fluid intake question is particularly interesting because the intuitive reasoning goes in two opposite directions. You might think that drinking more water would dilute carcinogens in the bladder and flush them out more often, reducing risk. Alternatively, if your water source contains arsenic or trihalomethanes, drinking more of it increases your exposure. The studies to date have not been able to disentangle these competing effects convincingly, and the net result is no clear overall association between total fluid volume and bladder cancer risk. What your water contains may matter more than how much of it you drink.